Back to Search
Start Over
In vitro testing of new somatostatin analogs on pituitary tumor cells.
- Source :
-
Molecular and cellular endocrinology [Mol Cell Endocrinol] 2008 May 14; Vol. 286 (1-2), pp. 187-91. Date of Electronic Publication: 2007 Dec 27. - Publication Year :
- 2008
-
Abstract
- Somatostatin has been discovered as a somatotroph release inhibitory factor (SRIF), and, indeed, it has been demonstrated that SRIF and its analogs can inhibit pituitary tumor hormone secretion and control neoplastic bulk. Several in vitro studies have contributed to the current knowledge of the mechanisms by which SRIF and its analogs may influence pituitary adenomas, opening the way to new possible therapeutic strategies. This review focuses on the results obtained by testing several SRIF analogs in vitro on pituitary adenomas, concerning both secretory activity and cell viability. These studies provide the basis for further investigations, both at basic and clinical level, of the application of SRIF analogs in the pituitary field.
- Subjects :
- Antineoplastic Agents, Hormonal pharmacology
Cell Survival drug effects
Drug Resistance, Neoplasm
Humans
Somatostatin pharmacology
Tumor Cells, Cultured
Adenoma drug therapy
Antineoplastic Agents, Hormonal therapeutic use
Pituitary Neoplasms drug therapy
Somatostatin analogs & derivatives
Somatostatin therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1872-8057
- Volume :
- 286
- Issue :
- 1-2
- Database :
- MEDLINE
- Journal :
- Molecular and cellular endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 18243520
- Full Text :
- https://doi.org/10.1016/j.mce.2007.12.010